|
**Overview**: **HAINS MTB Drug Resistance Profile****Introduction**: The HAINS MTB Drug Resistance Profile is a diagnostic tool designed to detect TB drug resistance using sputum samples. Associated with conditions like multidrug-resistant tuberculosis, these disorders present with persistent cough, fever, and severe complications if untreated, particularly in individuals with suspected TB. Per the 2023 Bacteriology and Molecular Pathology guidelines, the test employs bacteriology and molecular pathology with PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for TB drug resistance screening in clinical settings. This diagnostic falls under TB drug resistance screening and targets individuals with confirmed or suspected TB, addressing the challenge of accurate resistance assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its sputum-based approach ensures reliable detection.**Other Names**: HAINS MTB Pfl.**FDA Status**: FDA approved, CLIA certified for bacteriology and molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by infectious disease labs, this test advanced TB resistance diagnostics.**Purpose**: The test screens for 11 parameters including Mycobacterium tuberculosis to guide TB assessment, assess drug resistance patterns, and inform treatment and prevention strategies.**Test Parameters**: 1. Mycobacterium tuberculosis, 2. Rifampicin Resistance (rpoB), 3. Isoniazid Resistance (katG), 4. Isoniazid Resistance (inhA), 5. Fluoroquinolone Resistance (gyrA), 6. Fluoroquinolone Resistance (gyrB), 7. Aminoglycoside Resistance (rrs), 8. Kanamycin Resistance (eis), 9. Ethambutol Resistance (embB), 10. Pyrazinamide Resistance (pncA), 11. Streptomycin Resistance (rpsL).**Pretest Condition**: No fasting required; patients should report persistent cough, fever, or recent TB symptoms.**Specimen**: 2 mL sputum in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 1 month at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on persistent cough, fever, prior TB reactions, or family history of infectious diseases, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated TB including lung damage, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antibiotic use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible TB drug resistance, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in infectious disease should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Chest X-ray or culture for confirmation.**Test Limitations**: The test may produce false negatives in early infection stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Bacteriology and Molecular Pathology Guidelines 2023, Journal of Infectious Diseases 2024, Microbiology 2025. |
